Cancer Biopsy Market Size, Share & Growth Report 2034

1. Cancer Biopsy Market Size, Share & Growth Report 2034 What is Driving the Growth of the Cancer Biopsy Market? The cancer biopsy market is witnessing robust growth due to the rising global incidence of cancer, demand for early and accurate diagnostics, and technological advancements in biopsy techniques. Valued at USD 28.70 billion across the major markets in 2024, the industry is expected to expand at a CAGR of 13.20% during 2025–2034 to reach USD 99.16 billion by 2034. Biopsies remain the cornerstone of cancer diagnosis, enabling the collection and analysis of tissue or fluid samples to identify malignancies. With innovations such as liquid biopsy, advanced imaging-guided procedures, and molecular analysis platforms, the field of oncology diagnostics is undergoing rapid transformation. This report offers a comprehensive breakdown of the cancer biopsy market, answering the core questions stakeholders frequently search for. Cancer Biopsy Market Overview A cancer biopsy involves the removal of tissue, cells, or bodily fluids for microscopic and molecular examination to confirm the presence of cancer. The recent shift in biopsy methodologies stems from the need for minimally invasive, rapid, and highly sensitive diagnostic technologies. Traditional biopsy types such as needle, skin, and bone marrow biopsies continue to dominate clinical practice. At the same time, liquid biopsies—a non-invasive diagnostic method using blood samples—are gaining traction for their ability to provide real-time molecular profiling and monitor tumor progression. The biopsy industry is not only crucial in initial diagnosis but also in treatment planning, precision medicine, clinical trial recruitment, and relapse monitoring, making it a central component of oncology care. Cancer Biopsy Market: Key Growth Drivers ● Rising cancer prevalence: Increasing global cancer incidence drives demand for definitive diagnostic tools. ● Shift to minimally invasive biopsies: Reduced patient discomfort and faster turnaround times foster adoption of liquid and needle biopsies.

2. ● Growth of precision medicine: Biopsies are essential for tumor genomic profiling and personalized treatment selection. ● Integration with imaging technologies: MRI, CT, and ultrasound-guided biopsies improve procedural accuracy. ● Advancements in liquid biopsy: Enables repeated, real-time monitoring of tumor evolution without the need for invasive procedures. ● Investment in oncology R&D: Pharma and biotech companies use biopsies for patient stratification in clinical trials. Cancer Biopsy Market by Products and Services ● Kits and Consumables: Largest revenue share due to the recurring need for reagents, collection kits, and sample preparation tools. ● Instruments: Includes biopsy needles, forceps, and advanced imaging-guided systems supporting accurate tissue extraction. ● Services: Pathology and genomic sequencing services form a significant part of the market, especially with precision oncology demand. Cancer Biopsy Market by Type ● Needle Biopsy: Commonly used method, especially core and fine needle aspiration biopsies, preferred for accessible tumors. ● Skin Biopsies: Primarily used for diagnosing melanomas and skin cancers, continuing to stay relevant with rising skin cancer incidence. ● Bone Marrow Biopsies: Critical in diagnosing blood cancers such as leukemia, multiple myeloma, and lymphoma. ● Liquid Biopsies: Fastest-growing segment, offering the advantage of repeat sampling, tumor heterogeneity analysis, and minimal invasiveness. ● Other Biopsies: Includes surgical excisional biopsies, endoscopic biopsies, and punch biopsies catering to specific site-based cancers. Cancer Biopsy Market by Region ● United States: The largest market, driven by advanced diagnostic infrastructure, high cancer incidence, and oncology R&D investments. ● United Kingdom: Strong growth supported by national screening programs and government focus on early cancer detection. ● Germany: A leading EU market, with high adoption of precision oncology solutions and strong clinical research. ● France & Italy: Witness growing adoption of both traditional and liquid biopsy technologies due to cancer screening initiatives. ● Spain: Expanding healthcare capacity promotes increased biopsy volumes.

3. ● Japan: Rising cancer burden and adoption of molecular diagnostics fuel demand. Competitive Landscape: Key Companies The cancer biopsy market features established molecular diagnostic giants, device manufacturers, and emerging biotech innovators: ● QIAGEN – Known for molecular diagnostic kits supporting tissue and liquid biopsies. ● Illumina, Inc. – A leader in genomic sequencing integrated with biopsy sample analysis. ● ANGLE plc – Specializes in liquid biopsy platforms using Parsortix technology. ● BD (Becton, Dickinson and Company): Provider of biopsy needles and diagnostic tools. ● Bio-Rad Laboratories Inc. – Offers molecular assays for cancer biomarker detection. ● Hologic, Inc. – Strong presence in imaging-guided biopsy systems. ● BIOCEPT, INC. – Focuses on liquid biopsy tests for precision cancer diagnosis. ● Thermo Fisher Scientific, Inc. – Provides consumables and molecular analysis services for oncology diagnostics. ● F. Hoffmann-La Roche Ltd. – Expanding its portfolio with tissue and liquid biopsy companion diagnostics. ● Danaher – Through subsidiaries like Leica Biosystems, provides pathology tools for biopsy sample preparation and analysis. Future Outlook of the Cancer Biopsy Market The future of the cancer biopsy market rests on the advancement of liquid biopsy and genomics-driven oncology diagnostics. By 2034, non-invasive sampling methods will likely rival traditional tissue biopsies, reducing dependency on surgical interventions. Key future trends: ● Wider adoption of real-time liquid biopsy monitoring for therapy response ● Integration of AI-powered pathology systems to enhance diagnostic efficiency ● Surge in companion diagnostics enabling targeted therapies ● Expansion of point-of-care biopsy technologies for faster diagnostic turnaround ● Growth in clinical trial enrollments leveraging biopsy-based stratification With oncology precision therapy pipelines expanding, the demand for sensitive, repeatable, and patient-friendly biopsies will intensify, making the sector one of the most dynamic within diagnostic healthcare. Access More Reports Advanced Wound Care Market Artificial Insemination Market

4. Amyotrophic Lateral Sclerosis Market Dementia Drugs Market About Us: Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector. Media Contact: Company Name: Claight Corporation Contact Person: Roshan Kumar, Digital Marketing Email: sales@expertmarketresearch.com Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA Website: www.expertmarketresearch.com